Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.

Researchers have developed a new process that uses microwave flow reaction and recyclable solid catalysts to efficiently hydrolyze polysaccharides into simple sugars. The developed device utilizes a ...

Healthcare-focused AI startup Hippocratic AI has closed its Series B financing round, raising $141m, led by venture capital ...